NOS2 Is not Great for ER-Negative Cancer Of The Breast Patients

Breast cancer could be split into different subtypes according to several criteria, including whether they express the protein that the feminine hormone oestrogen binds that's, the oestrogen receptor (ER). Patients with ER-negative breast growths possess a worse outlook than individuals with ER-positive breast tumors.

However, even among ER-negative breast growths, individuals indicated as basal-like would be the most aggressive and hard to treat. New therapeutic targets with this subtype of cancer of the breast are urgently needed.

Now, a team of scientists, brought by Stefan Ambs, in the National Cancer Institute, Bethesda, report data that claim that the protein NOS2 might be a good drug target within this context. The information, produced by analysis of human breast cancer samples and cell lines, lead the authors to summarize that high amounts of NOS2 really are a predictor of survival in patients with ER-negative breast growths and also to claim that selective NOS2 inhibitors may be of great benefit to those people.

The study is reported within the Journal of Clinical Analysis.

Posted in HER2-positive breast cancer